Fourth Quarter & Full Year 2022 Financial & Business Update

Actively Investing to Broadly Leverage Vedotin ADC / Anti-PD1 Clinical Synergy to Drive Patient Response and Durability Vedotin ADCs have shown to combine well with anti-PD1s, amplifying their effect through immunogenic cell death Enhanced clinical benefit seen in multiple combination studies, including ADCETRIS, DV, TIVDAK and PADCEV 9+ combination trials ongoing and others planned PADCEV enfortumab vedotin-ejfv Injection for IV infusion 20 mg & 30 mg vials CADCETRIS brentuximab vedotin for Injection tivdak tisotumab vedotin-tftv for injection 40 mg Ladiratuzumab Vedotin Disitamab Vedotin + Others TBD Seagen® 11

View entire presentation